WTR Healthcare Happenings
WTR Healthcare Happenings is a weekly conversation with healthcare executives, medical experts, and investors on recent clinical data or industry-driving events in healthcare.
Episodes
45 episodes
Unmasking the Treatment Landscape for Obstructive Sleep Apnea (OSA)
Robert Sassoon, WTR Senior Healthcare Analyst, joins Tim Gerdeman to discuss obstructive sleep apnea (OSA) and the rapidly evolving treatment landscape for this widespread yet often undiagnosed and potentially fatal condition. The conversation ...
•
11:55
Psychedelics at a Turning Point: The Trials That Could Change Mental Health Treatment
Robert Sassoon, WTR Senior Healthcare Analyst, joins Shawn Severson, CEO of WTR, to break down the latest clinical readouts in advanced psychedelics — including Compass Pathways’ Phase III progress in treatment-resistant depression, new anxiety...
•
13:28
Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why 2026 Is Poised to Be a Defining Year
In this episode of the WTR Healthcare Happenings, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momen...
•
24:26
Omniscient Neurotechnology: Scaling up Clinical Connectomics SaaS Strategy and Neurotech Vision
In this episode of the WTR Healthcare Happenings, Adam Fraser, COO of Omniscient Neurotechnology—a privately held, Australian‑based but U.S.-focused company pioneering AI‑driven brain mapping—joins Water Tower Research Co‑Founder Tim Gerdeman a...
•
30:17
Decoy Therapeutics (DCOY): CEO Rick Pierce on the Company’s Groundbreaking Approach to Drug Development in the AI/ML Era
In this episode of the WTR Healthcare Happenings podcast, Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY), joins Tim Gerdeman, Vice Chair, Co‑Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst....
•
30:01
Medicus Pharma (MDCX): De‑Risking Drug Development to Capture a High‑Growth Market Opportunity
In this episode of WTR Healthcare Happenings, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX), joins Tim Gerdeman and Robert Sassoon to walk through the company’s strategy and market focus. Dr. Bokhari explains how...
•
33:55
NurExone Biologic (OTCQB: NRXBF / TSXV: NRX): CEO Dr. Lior Shaltiel on How the Company Stands Out as an Early‑Clinical‑Stage Biotech
In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (OTCQB: NRXBF / TSXV: NRX), joins Tim Gerdeman and Robert Sassoon to discuss how the company is positioning itself as a...
•
11:38
Taking Aim at Norovirus; Cocrystal Pharma's (COCP) Clinical Antiviral Opportunity
In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery p...
•
27:26
How Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG Biomarker
In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Thera...
•
28:12
Anixa' (ANIX) T-Cell Innovations Demonstrate Early Breakthrough Potential in Solid Tumors
In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explore...
•
13:09
The lure of the NASDAQ for Biotechs
In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.
•
7:11
Redefining Cancer Treatment: Calidi Biotherapeutics’ Approach to Enable Systemic Oncolytic Virotherapy for Metastatic Disease
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is sol...
•
18:38
Co-Diagnostic' Technology to Deliver Accessible, High-Fidelity Gold Standard PCR Testing Like No Other
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Dwight Egan, CEO of Co-Diagnostics Inc. (NASDAQ: CODX), about the company’s evolution from a pandemic-era PCR testing provider t...
•
19:47
CEO Jagi Gill on How Apyron' Innovative Neurostimulation Solution Breaks the Chronic Pain Barrier
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon talk with Apyron CEO Jagi Gill about the company's innovative neurostimulation technology for chronic pain, an all too prevalent afflictio...
•
22:05
RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing
•
16:28
Vivos Therapeutics’ Mission to Transform Sleep Treatment
In this WTR Healthcare Happenings Spotlight Flashcast, host Tim Gerdeman sits down with WTR's Healthcare Analyst Robert Sassoon to discuss his recently published initiation of coverage on Vivos Therapeutics (NASDAQ: VVOS). The conversation expl...
•
11:03
GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders
On the latest WTR Healthcare Happenings podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and co...
•
11:46
Ainos' Director of Corporate Development Jack Lu Discusses the AI Nose Platform' continuing 2025 momentum and Looks Ahead into 2026
In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD) to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into ...
•
15:21
The Psychedelic Investment Environment: A New Era of Optimism
Hear about the latest dynamic developments in the therapeutic psychedelics sector in our WTR Healthcare Happenings Flashcast. Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer at WTR, and Robert Sassoon, WTR's Senior Healthc...
•
10:00
Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation
In this episode of WTR Healthcare Happenings, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and ...
•
22:37
Reversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve Injuries
In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (TSXV: NRX | OTCQB: NRXBF), and Yoram Drucker, Founder, VP of Business Development, and Active Chairman, join host Tim Gerdeman, Vice Chair and C...
•
16:56
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores t...
•
Season 1
•
Episode 24
•
20:37
CEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid Tumors
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Amit Kumar, PhD, CEO of Anixa Biosciences (NASDAQ: ANIX) to discuss t-cells and Anixa's two clinical developments,...
•
Season 1
•
Episode 23
•
24:18
Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market
We welcome back Veru's CEO Mitch Steiner to our latest WTR Healthcare Happenings podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosar...
•
Season 1
•
Episode 22
•
21:35
Revolutionizing Stroke Prevention: InspireMD’s CGuard® Prime and the Future of Carotid Stenting
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Marvin Slosman, CEO of InspireMD (NASDAQ: NSPR), to discuss how the company is transforming carotid artery disease...
•
Season 1
•
Episode 21
•
19:15